Acute Promyelocytic Leukemia (PML-RARA) · line 2 · ATRA + ATO salvage for R/R APL post front-line
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 2 |
|---|---|
| Track | aggressive |
| Linked regimen | REG-ATRA-ATO-APL-SALVAGE |
| ID | IND-APL-SALVAGE-ATRA-ATO |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | DIS-APL |
| Sources | SRC-APL-RELAPSE-LENGFELDER-2017 SRC-ELN-APL-2019 SRC-NCCN-AML-2025 |
Notes
STUB — pending Clinical Co-Lead sign-off. Aggressive-track 2L for relapsed APL post-front-line. ATRA + ATO available in Ukraine — salvage pathway feasible domestically. AutoSCT consolidation for fit molecularly-CR.
Used By
Algorithms
ALGO-APL-2L- ALGO-APL-2L